Novartis withdraws bid to block US Regeneron imports
04-05-2021
GSK buys out Novartis in $13bn consumer healthcare deal
27-03-2018
kadmy / iStockphoto.com
Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea (aflibercept) and Zaltrap (ziv-aflibercept).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, Regeneron, eye disorder, retina disorder, Lucentis, Eylea, Zaltrap, District Court for the Southern District of New York, patented medical techno
